Considering the potentially important role of macrophage activation in the progression of L-CRS and S-CRS, we have previously attempted to control the inflammatory response by inhibiting macrophage activation using TNF-a blocking drugs82 in the patients with a high tumour burden (SPD ≥ 100 cm2). Here, TNF is linked to congenital rubella syndrome.